-
公开(公告)号：US20190216882A1
公开(公告)日：2019-07-18
申请号：US16227994
申请日：2018-12-20
Applicant: AbbVie Inc.
Inventor： Nancy E. Sever , Ulrich Westedt , Ute Lander , Katrin Schneider , Benedikt Steitz , Thomas Mueller , Regina Reul , Constanze Obermiller , Adivaraha Jayasankar , Michael Simon , Yi Gao , Harald Hach , Samuel Kyeremateng , Katharina Asmus , Ping Tong , Donghua Zhu , Marius Naris , Colleen Garrett
IPC: A61K38/06 , A61K31/4184 , A61K31/498 , A61K31/454 , A61K9/24 , A61K9/16 , A61K9/20 , A61K9/14 , A61K9/28
CPC classification number: A61K38/06 , A61K9/146 , A61K9/1688 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/209 , A61K9/2866 , A61K31/4184 , A61K31/454 , A61K31/498 , A61K2300/00
Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.
-
公开(公告)号：US20170368066A1
公开(公告)日：2017-12-28
申请号：US15639424
申请日：2017-06-30
Applicant: AbbVie Inc.
Inventor： Jonathan M. Miller , John B. Morris , Nancy E. Sever , Eric A. Schmitt , Ping X. Gao , Yi Shi , Yi Gao , Bernd Liepold , Anna Moosmann , Mirko Pauli , Fatih Durak , Thomas Kessler , Peter Hoelig , Karin Rosenblatt , Drazen Kostelac , Rajeev Gokhale , Mark Costello , Carl Knable
IPC: A61K31/513 , A61K47/38 , A61K31/4025 , A61K9/24 , A61K31/427 , A61K31/497 , A61K47/32
CPC classification number: A61K31/513 , A61K9/209 , A61K31/4025 , A61K31/427 , A61K31/497 , A61K47/32 , A61K47/38 , A61K2300/00
Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.
-
公开(公告)号：US20160199374A1
公开(公告)日：2016-07-14
申请号：US15073767
申请日：2016-03-18
Applicant: AbbVie Inc.
Inventor： Jonathan M. Miller , John B. Morris , Nancy E. Sever , Eric A. Schmitt , Ping X. Gao , Yi Shi , Yi Gao , Bernd Liepold , Anna Moosmann , Mirko Pauli , Fatih Durak , Thomas Kessler , Peter Hoelig , Karin Rosenblatt , Drazen Kostelac , Rajeev Gokhale , Mark Costello , Carl Knable
IPC: A61K31/513 , A61K47/38 , A61K31/427 , A61K47/32 , A61K31/497 , A61K31/4025
CPC classification number: A61K31/513 , A61K9/209 , A61K31/4025 , A61K31/427 , A61K31/497 , A61K47/32 , A61K47/38 , A61K2300/00
Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.
-
公开(公告)号：US20200253968A1
公开(公告)日：2020-08-13
申请号：US16654442
申请日：2019-10-16
Applicant: AbbVie Inc.
Inventor： Nancy E. Sever , Ulrich Westedt , Ute Lander , Katrin Schneider , Benedikt Steitz , Thomas Mueller , Regina Reul , Constanze Obermiller , Adivaraha Jayasankar , Michael Simon , Yi Gao , Harald Hach , Samuel Kyeremateng , Katharina Asmus , Ping Tong , Donghua Zhu , Marius Naris , Colleen Garrett
IPC: A61K31/498 , A61K31/454 , A61K9/24 , A61K9/20 , A61K9/14 , A61K31/4985
Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.
-
公开(公告)号：US09744170B2
公开(公告)日：2017-08-29
申请号：US15073767
申请日：2016-03-18
Applicant: AbbVie Inc.
Inventor： Jonathan M. Miller , John B. Morris , Nancy E. Sever , Eric A. Schmitt , Ping X. Gao , Yi Shi , Yi Gao , Bernd Liepold , Anna Moosmann , Mirko Pauli , Fatih Durak , Thomas Kessler , Peter Hoelig , Karin Rosenblatt , Drazen Kostelac , Rajeev Gokhale , Mark Costello , Carl Knable
IPC: A61K31/513 , A61K31/4025 , A61K31/427 , A61K31/497 , A61K47/32 , A61K47/38 , A61K9/24
CPC classification number: A61K31/513 , A61K9/209 , A61K31/4025 , A61K31/427 , A61K31/497 , A61K47/32 , A61K47/38 , A61K2300/00
Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.
-
Patent Agency Ranking
公开(公告)号：US11246866B2
公开(公告)日：2022-02-15
申请号：US16654442
申请日：2019-10-16
Applicant: AbbVie Inc.
Inventor： Nancy E. Sever , Ulrich Westedt , Ute Lander , Katrin Schneider , Benedikt Steitz , Thomas Mueller , Regina Reul , Constanze Obermiller , Adivaraha Jayasankar , Michael Simon , Yi Gao , Harald Hach , Samuel Kyeremateng , Katharina Asmus , Ping Tong , Donghua Zhu , Marius Naris , Colleen Garrett
IPC: A61K31/498 , A61K9/28 , A61K9/20 , A61K31/454 , A61K9/24 , A61K9/14 , A61K31/4985
Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.
-
公开(公告)号：US20200282004A1
公开(公告)日：2020-09-10
申请号：US16654433
申请日：2019-10-16
Applicant: AbbVie Inc.
Inventor： Nancy E. Sever , Ulrich Westedt , Ute Lander , Katrin Schneider , Benedikt Steitz , Thomas Mueller , Regina Reul , Constanze Obermiller , Adivaraha Jayasankar , Michael Simon , Yi Gao , Harald Hach , Samuel Kyeremateng , Katharina Asmus , Ping Tong , Donghua Zhu , Marius Naris , Colleen Garrett
IPC: A61K38/06 , A61K9/14 , A61K9/20 , A61K9/24 , A61K31/454 , A61K31/498 , A61K9/16 , A61K9/28 , A61K31/4184
Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.
-
公开(公告)号：US20150258093A1
公开(公告)日：2015-09-17
申请号：US14677611
申请日：2015-04-02
Applicant: AbbVie Inc. , AbbVie Deutschland GmbH & Co. KG
Inventor： Jonathan M. Miller , John B. Morris , Nancy E. Sever , Eric A. Schmitt , Ping X. Gao , Yi Shi , Yi Gao , Bernd Liepold , Anna Moosmann , Mirko Pauli , Fatih Durak , Thomas Kessler , Peter A. Hoelig , Karin Rosenblatt , Drazen Kostelac , Rajeev Gokhale , Mark Costello , Carl Knable
IPC: A61K31/513 , A61K31/4025 , A61K31/427 , A61K31/497
CPC classification number: A61K31/513 , A61K9/209 , A61K31/4025 , A61K31/427 , A61K31/497 , A61K47/32 , A61K47/38 , A61K2300/00
Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.
Abstract translation: 本公开涉及包含抗病毒化合物的固体剂型和使用这些剂型来治疗抗病毒感染的方法。
-
公开(公告)号：US20140171481A1
公开(公告)日：2014-06-19
申请号：US14180531
申请日：2014-02-14
Applicant: AbbVie, Inc.
Inventor： Bernd Liepold , Tina Jung , Peter H?lig , Rudolf Schroeder , Nancy E. Sever , Justin S. Lafountaine , Brent D. Sinclair , Yi Gao , Jianwei Wu
IPC: A61K31/4025
CPC classification number: A61K31/4025 , A61K9/146 , A61K9/1617 , A61K9/1635 , A61K9/1694 , A61K9/2027 , A61K9/2054 , A61K31/00
Abstract: The present invention features solid compositions comprising amorphous Compound I. For instance, Compound I may be formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.
Abstract translation: 本发明的特征在于包含无定形化合物I的固体组合物。例如，化合物I可以配制成包含药学上可接受的亲水聚合物，优选药学上可接受的表面活性剂的无定形固体分散体
-
公开(公告)号：US20240075026A1
公开(公告)日：2024-03-07
申请号：US18107243
申请日：2023-02-08
Applicant: AbbVie Inc.
Inventor： Nancy E. Sever , Ulrich Westedt , Ute Lander , Katrin Schneider , Benedikt Steitz , Thomas Mueller , Regina Reul , Constanze Obermiller , Adivaraha Jayasankar , Michael Simon , Yi Gao , Harald Hach , Samuel Kyeremateng , Katharina Asmus , Ping Tong , Donghua Zhu , Marius Naris , Colleen Garrett
IPC: A61K31/498 , A61K9/14 , A61K9/20 , A61K9/24 , A61K31/454 , A61K31/4985
CPC classification number: A61K31/498 , A61K9/146 , A61K9/2027 , A61K9/209 , A61K31/454 , A61K31/4985
Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.015 seconds)
